Lucence Health Inc. services

LiquidHALLMARK® is an ultrasensitive next-generation sequencing assay for genomic profiling of a patient’s unique cancer. By requiring only a single blood sample, LiquidHALLMARK provides important information for cancer care especially when tissue by invasive biopsy is insufficient or inaccessible.

You can choose a painless and convenient COVID-19 Saliva Pre-Departure Test with our approved partner clinics today. Singapore has established Vaccinated Travel Lanes (VTL) with a growing list of countries which will allow quarantine-free travel for eligible vaccinated travellers. Starting November 2021, saliva-based pre-departure tests have been accepted in several regions including United States of America, Australia, Canada, Korea, Switzerland, Taiwan and Japan. Check the travel advisories of your destination country to find out if you are eligible for COVID-19 Saliva Pre-Departure Test.

HemeMARK™ is a next-generation sequencing assay that analyzes 45 cancer-related gene mutations in hematological malignancies including myeloid and lymphoid neoplasms.

Tissue500™ is a comprehensive genomic profiling test that detects clinically relevant mutations in 572 genes to identify a patient’s unique cancer signature.

AmpliMark is the foundational technology behind Lucence’s liquid biopsy tests. AmpliMark uses unique molecular barcodes in this error-correction technology. It is designed to improve detection of multiple mutation types like single nucleotide variants, insertions and deletions (indels), copy number variations (CNVs), fusions and microsatellite instability (MSI).